These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 36534151

  • 1. Risk and predictors of adverse pathology after radical prostatectomy in patients diagnosed with IUSP 1-2 prostate cancer at MRI-targeted biopsy: a multicenter analysis.
    Kesch C, Pantea V, Soeterik T, Marquis A, la Bombarda G, Morlacco A, Barletta F, Radtke JP, Darr C, Preisser F, Zattoni F, Marra G, van den Bergh RCN, Hadaschik B, Gandaglia G, EAU-YAU Prostate Cancer Working Party.
    World J Urol; 2023 Feb; 41(2):427-434. PubMed ID: 36534151
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillance.
    Ploussard G, Beauval JB, Lesourd M, Almeras C, Assoun J, Aziza R, Gautier JR, Loison G, Portalez D, Salin A, Tollon C, Soulié M, Malavaud B, Roumiguié M.
    World J Urol; 2020 Mar; 38(3):663-671. PubMed ID: 31197523
    [Abstract] [Full Text] [Related]

  • 6. Role of prostate health index to predict Gleason score upgrading and high-risk prostate cancer in radical prostatectomy specimens.
    Kim H, Jung G, Kim JH, Byun SS, Hong SK.
    Sci Rep; 2021 Aug 31; 11(1):17447. PubMed ID: 34465825
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tumor upgrading among very favorable intermediate-risk prostate cancer patients treated with robot-assisted radical prostatectomy: how can it impact the clinical course?
    Porcaro AB, Bianchi A, Panunzio A, Gallina S, Serafin E, Tafuri A, Trabacchin N, Orlando R, Ornaghi PI, Mazzucato G, Vidiri S, D'Aietti D, Montanaro F, Brusa D, Patuzzo GM, Artoni F, Baielli A, Migliorini F, De Marco V, Veccia A, Brunelli M, Siracusano S, Cerruto MA, Antonelli A.
    Int Urol Nephrol; 2024 Aug 31; 56(8):2597-2605. PubMed ID: 38553619
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinicopathological factors associated with pathological upgrading from biopsy to prostatectomy in patients with ISUP grade group ≤2 prostate cancer.
    Li X, Wang ZX, Zhu YP, Wang J, Yin YS, Zeng XY.
    Asian J Androl; 2022 Aug 31; 24(5):487-493. PubMed ID: 35170453
    [Abstract] [Full Text] [Related]

  • 12. A multicentric study on accurate grading of prostate cancer with systematic and MRI/US fusion targeted biopsies: comparison with final histopathology after radical prostatectomy.
    Diamand R, Oderda M, Al Hajj Obeid W, Albisinni S, Van Velthoven R, Fasolis G, Simone G, Ferriero M, Roche JB, Piechaud T, Pastore A, Carbone A, Fiard G, Descotes JL, Marra G, Gontero P, Altobelli E, Papalia R, Kumar P, Eldred-Evans D, Giacobbe A, Muto G, Lacetera V, Beatrici V, Roumeguere T, Peltier A.
    World J Urol; 2019 Oct 31; 37(10):2109-2117. PubMed ID: 30652213
    [Abstract] [Full Text] [Related]

  • 13. The role of perilesional and multiparametric resonance imaging-targeted biopsies to reduce the risk of upgrading at radical prostatectomy pathology: A retrospective monocentric study.
    Diamand R, Hollans M, Lefebvre Y, Sirtaine N, Limani K, Hawaux E, Abou Zahr R, Mattlet A, Albisinni S, Roumeguère T, Peltier A.
    Urol Oncol; 2022 May 31; 40(5):192.e11-192.e17. PubMed ID: 35236622
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Risk of adverse pathology at prostatectomy in the era of MRI and targeted biopsies; rethinking active surveillance for intermediate risk prostate cancer patients.
    Bloom JB, Daneshvar MA, Lebastchi AH, Ahdoot M, Gold SA, Hale G, Mehralivand S, Sanford T, Valera V, Wood BJ, Choyke PL, Merino MJ, Turkbey B, Parnes HL, Pinto PA.
    Urol Oncol; 2021 Oct 31; 39(10):729.e1-729.e6. PubMed ID: 33736975
    [Abstract] [Full Text] [Related]

  • 19. MRI-Fusion Targeted vs. Systematic Prostate Biopsy-How Does the Biopsy Technique Affect Gleason Grade Concordance and Upgrading After Radical Prostatectomy?
    Rührup J, Preisser F, Theißen L, Wenzel M, Roos FC, Becker A, Kluth LA, Bodelle B, Köllermann J, Chun FKH, Mandel P.
    Front Surg; 2019 Oct 31; 6():55. PubMed ID: 31620444
    [Abstract] [Full Text] [Related]

  • 20. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
    Gandaglia G, Ploussard G, Valerio M, Marra G, Moschini M, Martini A, Roumiguié M, Fossati N, Stabile A, Beauval JB, Malavaud B, Scuderi S, Barletta F, Afferi L, Rakauskas A, Gontero P, Mattei A, Montorsi F, Briganti A.
    Eur Urol Oncol; 2020 Dec 31; 3(6):739-747. PubMed ID: 32847747
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.